MedTrace Logo

Risk-stratified Osteoporosis Strategy Evaluation Study (ROSE)

NCT01388244 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35000

Last updated 2023-11-02

No results posted yet for this study

Summary

The Risk-stratified Osteoporosis Strategy Evaluation Study (ROSE) is a randomised population-based study, including 20,904 Danish women aged 65-80 years, investigating the effectiveness of a two-step screening programme for osteoporosis, using a questionnaire based on FRAX® followed by DXA-scan of those at highest risk. Further, the study is expected to provide knowledge about cost-effectiveness, patient preferences and acceptance of screening programme to prevent fractures

Conditions

Interventions

OTHER

Screening

Screening by risk factor assessment (FRAX) followed by DXA

OTHER

Control

Observation by use of register data

Sponsors & Collaborators

  • University of Southern Denmark

    collaborator OTHER

  • University Hospital Schleswig-Holstein

    collaborator OTHER

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Kim Brixen, Professor · University og Southern Denmark, Odense University Hospital, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01388244 on ClinicalTrials.gov